Literature DB >> 27795366

Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.

Henry W Murray1, Andrew D Luster2, Hua Zheng3, Xiaojing Ma3,4.   

Abstract

In the livers of C57BL/6 mice, gamma interferon (IFN-γ) controls intracellular Leishmania donovani infection and the efficacy of antimony (Sb) chemotherapy. Since both responses usually correlate with granulomatous inflammation, we tested six prominently expressed, IFN-γ-regulated chemokines-CXCL9, CXCL10, CXCL13, CXCL16, CCL2, and CCL5-for their roles in (i) mononuclear cell recruitment and granuloma assembly and maturation, (ii) initial control of infection and self-cure, and (iii) responsiveness to Sb treatment. Together, the results for the L. donovani-infected livers of chemokine-deficient mice (CXCR6-/- mice were used as CXCL16-deficient surrogates) indicated that individual IFN-γ-induced chemokines have diverse affects and (i) may be entirely dispensable (CXCL13, CXCL16), (ii) may promote (CXCL10, CCL2, CCL5) or downregulate (CXCL9) initial granuloma assembly, (iii) may enhance (CCL2, CCL5) or hinder (CXCL10) early parasite control, (iv) may promote granuloma maturation (CCL2, CCL5), (v) may exert a granuloma-independent action that enables self-cure (CCL5), and (vi) may have no role in responsiveness to chemotherapy. Despite the near absence of tissue inflammation in early-stage infection, parasite replication could be controlled (in CXCL10-/- mice) and Sb was fully active (in CXCL10-/-, CCL2-/-, and CCL5-/- mice). These results characterize chemokine action in the response to L. donovani and also reemphasize that (i) recruited mononuclear cells and granulomas are not required to control infection or respond to Sb chemotherapy, (ii) granuloma assembly, control of infection, and Sb's efficacy are not invariably linked expressions of the same T cell-dependent, cytokine-mediated antileishmanial mechanism, and (iii) granulomas are not necessarily hallmarks of protective antileishmanial immunity.
Copyright © 2016 American Society for Microbiology.

Entities:  

Keywords:  Leishmania donovani; chemokines; granuloma; pentavalent antimony; visceral leishmaniasis

Mesh:

Substances:

Year:  2016        PMID: 27795366      PMCID: PMC5203646          DOI: 10.1128/IAI.00824-16

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  73 in total

1.  Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology.

Authors:  Lucia E Rosas; Anjali A Satoskar; Kimberly M Roth; Tracy L Keiser; Joseph Barbi; Christopher Hunter; Frederic J de Sauvage; Abhay R Satoskar
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

Review 2.  Tissue granuloma structure-function in experimental visceral leishmaniasis.

Authors:  H W Murray
Journal:  Int J Exp Pathol       Date:  2001-10       Impact factor: 1.925

3.  Effect of blocking the CXCL9/10-CXCR3 chemokine system in the outcome of endothelial-target rickettsial infections.

Authors:  Gustavo Valbuena; David H Walker
Journal:  Am J Trop Med Hyg       Date:  2004-10       Impact factor: 2.345

4.  Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice.

Authors:  Mark D Wareing; Ashley B Lyon; Bao Lu; Craig Gerard; Sally R Sarawar
Journal:  J Leukoc Biol       Date:  2004-07-07       Impact factor: 4.962

5.  Visceral Leishmania donovani infection in interleukin-13-/- mice.

Authors:  Henry W Murray; Christine W Tsai; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

6.  Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani.

Authors:  Emma McFarlane; Cynthia Perez; Mélanie Charmoy; Cindy Allenbach; K Christine Carter; James Alexander; Fabienne Tacchini-Cottier
Journal:  Infect Immun       Date:  2007-12-03       Impact factor: 3.441

7.  Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21.

Authors:  Manabu Ato; Asher Maroof; Soombul Zubairi; Hideki Nakano; Terutaka Kakiuchi; Paul M Kaye
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

8.  CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi.

Authors:  Fabiana S Machado; Natalia S Koyama; Vanessa Carregaro; Beatriz R Ferreira; Cristiane M Milanezi; Mauro M Teixeira; Marcos A Rossi; João S Silva
Journal:  J Infect Dis       Date:  2005-01-13       Impact factor: 5.226

9.  Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani.

Authors:  H W Murray; C F Nathan
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

10.  Deficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani.

Authors:  Forough Khadem; Zhirong Mou; Dong Liu; Sanjay Varikuti; Abhay Satoskar; Jude E Uzonna
Journal:  PLoS Negl Trop Dis       Date:  2014-06-19
View more
  9 in total

1.  Leishmania donovani Lipophosphoglycan Increases Macrophage-Dependent Chemotaxis of CXCR6-Expressing Cells via CXCL16 Induction.

Authors:  Visnu Chaparro; Louis-Philippe Leroux; Aude Zimmermann; Armando Jardim; Brent Johnston; Albert Descoteaux; Maritza Jaramillo
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

2.  Cutting Edge: Bacillus Calmette-Guérin-Induced T Cells Shape Mycobacterium tuberculosis Infection before Reducing the Bacterial Burden.

Authors:  Jared L Delahaye; Benjamin H Gern; Sara B Cohen; Courtney R Plumlee; Shahin Shafiani; Michael Y Gerner; Kevin B Urdahl
Journal:  J Immunol       Date:  2019-07-15       Impact factor: 5.422

Review 3.  Epigenetic paradigms/exemplars of the macrophage: inflammasome axis in Leishmaniasis.

Authors:  Manei M Aljedaie
Journal:  Mol Cell Biochem       Date:  2022-05-20       Impact factor: 3.396

4.  Targeting IL-27 and/or IL-10 in Experimental Murine Visceral Leishmaniasis.

Authors:  Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2020-11       Impact factor: 2.345

5.  Triterpenoids Extracted From Antrodia cinnamomea Mycelia Attenuate Acute Alcohol-Induced Liver Injury in C57BL/6 Mice via Suppression Inflammatory Response.

Authors:  Yange Liu; Zhuqian Wang; Fange Kong; Lesheng Teng; Xiaoyi Zheng; Xingkai Liu; Di Wang
Journal:  Front Microbiol       Date:  2020-07-03       Impact factor: 5.640

6.  RNA-Seq Revealed Expression of Many Novel Genes Associated With Leishmania donovani Persistence and Clearance in the Host Macrophage.

Authors:  Mohammad Shadab; Sonali Das; Anindyajit Banerjee; Roma Sinha; Mohammad Asad; Mohd Kamran; Mithun Maji; Baijayanti Jha; Makaraju Deepthi; Manoharan Kumar; Abhishek Tripathi; Bipin Kumar; Saikat Chakrabarti; Nahid Ali
Journal:  Front Cell Infect Microbiol       Date:  2019-02-05       Impact factor: 5.293

7.  Cytokine Gene Expression Alterations in Human Macrophages Infected by Leishmania major.

Authors:  Khodaberdi Kalavi; Ogholniaz Jorjani; Mohammad Ali Faghihi; Seyed Javad Mowla
Journal:  Cell J       Date:  2020-04-22       Impact factor: 2.479

8.  In vitro and in vivo immunomodulatory properties of octyl-β-D-galactofuranoside during Leishmania donovani infection.

Authors:  Hélène Guegan; Kevin Ory; Sorya Belaz; Aurélien Jan; Sarah Dion; Laurent Legentil; Christelle Manuel; Loïc Lemiègre; Thomas Vives; Vincent Ferrières; Jean-Pierre Gangneux; Florence Robert-Gangneux
Journal:  Parasit Vectors       Date:  2019-12-23       Impact factor: 3.876

9.  Protection mediated by chemokine CXCL10 in BALB/c mice infected by Leishmania infantum.

Authors:  Webertty Mayk Eufrásio Figueiredo; Sayonara de Melo Viana; Dorotheia Teixeira Alves; Priscila Valera Guerra; Zirlane Castelo Branco Coêlho; Helene Santos Barbosa; Maria Jania Teixeira
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-08       Impact factor: 2.743

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.